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Abstract
DNA damaging chemotherapy is a cornerstone of current front-line treatments for advanced ovar-
ian cancer (OC). Despite the fact that a majority of these patients initially respond to therapy, most
will relapse with chemo-resistant disease; therefore, adjuvant treatments that synergize with
DNA-damaging chemotherapy could improve treatment outcomes and survival in patients with
this deadly disease. Here, we report the development of a nanoscale peptide-nucleic acid complex
that facilitates tumor-specific RNA interference therapy to chemosensitize advanced ovarian
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tumors to frontline platinum/taxane therapy. We found that the nanoplex-mediated silencing of
the protein kinase, MK2, profoundly sensitized mouse models of high-grade serous OC to cyto-
toxic chemotherapy by blocking p38/MK2-dependent cell cycle checkpoint maintenance.
Combined RNAi therapy improved overall survival by 37% compared with platinum/taxane chemo-
therapy alone and decreased metastatic spread to the lungs without observable toxic side effects.
These findings suggest (a) that peptide nanoplexes can serve as safe and effective delivery vectors
for siRNA and (b) that combined inhibition of MK2 could improve treatment outcomes in patients
currently receiving frontline chemotherapy for advanced OC.
K E YWORD S
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1 | INTRODUCTION
RNA interference (RNAi) therapy is a powerful treatment strategy that
can be used to transiently deplete disease-causing proteins.1 While
promising, systemic administration of RNAi therapeutics such as small
interfering RNA (siRNA) in patients is challenging due to rapid urinary
clearance, nuclease degradation, and inefficient tissue, cellular, or cyto-
solic delivery. Formulation strategies for siRNA based on phospho-
lipid2,3 and lipid-like4,5 carriers have conferred therapeutic benefits in
animal disease models and in clinical trials6,7; however, efficient tissue-
specific delivery beyond the liver, and avoidance of dose-limiting side
effects remains a key challenge for the field. In contrast to antisense
oligonucleotide therapies that have been FDA approved since 1998, no
siRNA-based therapies have been approved to-date.
Polymer-based drug carriers8–14 represent a versatile and potentially
safe alternative to lipidic oligonucleotide drug carriers, and related archi-
tectures have been utilized in a range of clinically approved drug formula-
tions for more than three decades. Due to their modular nature, polymers
can be engineered to package, protect, and deliver siRNAs to tumors, and
can afford therapeutic nucleic acids access to the cytosol where they can
inhibit the expression of oncogenic and pro-survival genes, among others.
Recently, we demonstrated that a family of polypeptides synthesized by
N-carboxyanhydride (NCA) ring-opening polymerization15–17 can serve as
modular scaffolds for the delivery of both small molecule drugs16,18,19 and
nucleic acids.20 Previous strategies to formulate siRNA using synthetic
polypeptides have focused largely on the formation of electrostatic com-
plexes with cationic block copolymers.21 The resulting systems facilitate
efficient complexation of nucleic acids; however, highly charged polyca-
tionic blocks can be challenging to engineer such that siRNAs are effi-
ciently released from complexes entrapped within endosomal
compartments. Design strategies for nucleic acid carriers thus require a
balance between high valency of charge (complexation) and intracellular
release or cytotoxicity. In place of a more traditional diblock copolymer
with a charged or neutral water-soluble block, we have engineered a fam-
ily of NCA polymers derived from short oligopeptides that spatially isolate
varying delivery functions within the final nanoparticle (Figure 1a). By low-
ering the charge density of the positively charged component and intro-
ducing other intermolecular interactions, here we can employ a more
dynamic polyelectrolyte complex system than the typical ionically cross-
linked matrix. Supramolecular NCA architectures in which siRNA is elec-
trostatically complexed within a dynamically complexed core could thus
provide new opportunities for tumor-targeted siRNA delivery in vivo.
Despite many encouraging advances in addressing other common
cancers such as breast and prostate cancer, there has been little to no
improvement in the survival rate of ovarian cancer (OC) patients over the
past 30 years.22 The 5-year survival rates for the disease have hovered at
approximately 30–40% in the past several decades, and OC is now the
fifth most lethal cancer for women.23 Today, nearly all patients diagnosed
with epithelial OC will be treated with DNA-damaging platinum-based
chemotherapy.24 Particularly for advanced serous OC, surgical debulking
followed by platinum therapy is the treatment of choice. Of these
patients, approximately 20–30% will not respond to the initial therapy,
and of the remaining patients, approximately 70% eventually relapse with
a platinum-resistant form of the disease.25 Methods to sensitize aggres-
sive or recurrent ovarian tumors to platinum chemotherapy could thus
improve response rates and overall survival following diagnosis, which
most often occurs in advanced stages. Recently, we identified a
p38MAPK/MK2-dependent DNA damage response pathway that is
selectively required for survival of cells deficient in the tumor suppressor,
p53.26–29 We found28 that loss of the protein kinase, MK2, profoundly
sensitized non-small cell lung cancers to DNA damaging chemotherapy in
vivo, resulting from corresponding loss of cell cycle checkpoint mainte-
nance and subsequent mitotic catastrophe.27 Importantly, we observed
that loss of this response pathway is inconsequential in normal (i.e., p53-
proficient) cells, thus limiting chemosensitization to tumor cells harboring
genetic mutations in the p53 tumor suppressor protein.26–29 Given that
TP53 mutation and/or loss is a hallmark of high-grade serous OC and is
observed in >96% of patients,30 we seek here to develop this therapeu-
tic approach for the treatment of OC.
Although MK2 is a promising drug target due to its role in both can-
cer and inflammation, commercial development of small molecule inhibi-
tors against the protein have experienced little clinical success due in
part to the kinase’s shallow binding pocket and sequence homology with
other physiologically important kinases (e.g., MK3, MK5, MNK1, MNK2).
Furthermore, MK2 plays an important role in the immune response.31
Thus, highly selective and tissue-specific silencing of this “undruggable”
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target in tumors represents a novel and unmet clinical need, and pro-
vides the opportunity to utilize engineered nanocarriers to deliver che-
mosensitizing siRNA with concurrent cytotoxic chemotherapy for the
treatment of advanced serous OC. We hypothesize that RNAi of MK2
mediated by synthetic peptide nanoplexes may sensitize p53-deficient
ovarian tumors to DNA damaging chemotherapy and improve treatment
outcomes in OC patients receiving frontline platinum/taxane therapy;
here, we demonstrate their therapeutic performance in vitro and in
orthotopic mouse models of late stage, high-grade serous OC.
2 | MATERIALS AND METHODS
2.1 | Materials
Silencer Select siRNA targeting human MAPKAPK2 (s569; Thermo
Fischer); sense: GGAUCAUGCAAUCAACAAATT, antisense: UUUGUU
GAUUGCAUGAUCCAA. Antibodies included: p-P38 (CST 4511S),
MK2-WB (CST 3042), vinculin (Abcam ab18058), MK2-IHC (Bioworld
BS3766), Ki-67 (Abcam ab16667), cleaved caspase-3 (CST 9661),
PAX8 (Proteintech 10336-1-AP), and WT1 (Abcam ab89901).
2.2 | Nanoplex assembly and analysis
Peptides (96:2:2 mol% cation:helper:PEG; CHCl3; N:P51) were ali-
quoted into sterile chromatography vials, dried under N2, and reconsti-
tuted with DMSO. Aqueous siRNA solution was added to >60% v/v
and the mixture was diluted 20-fold with a 50% ethanol : water (ca.
0.5 mL/min) under sonication at RT. Peptide-siRNA complexes were
purified by dialysis (3.5-5 kDa) against ultrapure water at 48C and diluted
in 13 PBS immediately prior to injection by dropwise addition of 103
PBS buffer with sonication at RT. siRNA encapsulation efficiency was
FIGURE 1 Rational design of a synthetic peptide nanoplex for RNA interference therapy. (a) Synthetic scheme to obtain end-functional N-car-
boxyanhydride (NCA) polymers via ring-opening polymerization of benzyl L-aspartate, yielding peptides that facilitate nucleic acid binding, nucle-
ase shielding, or cytosolic delivery. Solvent dilution in the presence of siRNA produces (b) nanometer-scale polyelectrolyte complexes that are (c)
net-neutral in charge as measured by dynamic light scattering (DLS). (d) Cryogenic transmission electron microscopy (cryo-TEM) of RNA-peptide
nanoplexes indicating spherical morphology in the hydrated state and (e) electron microscopy of dehydrated nanoparticles formed using gold
nanoparticle-labeled siRNA showing homogeneous siRNA distribution throughout the ionic complex core. (f) Nanoplex stability (critical aggrega-
tion concentration) as measured by pyrene fluorescence assay. (g) Live-cell confocal fluorescence microscopy of nanoplex-mediated cell transfec-
tion illustrating cytosolic delivery of siRNA (green) relative to acidic organelles (red) and nuclei (blue). (h) Fluorescence imaging tomography (FLIT)
of nanoplex-delivered siRNA distributed throughout an OVCAR3 hind-flank xenograft tumor model following intraperitoneal administration. Data
in (b–h) were obtained at an N-to-P ratio of 1. (f) 335 nm ex, 373 nm em (I1), 384 nm em (I3). (g) 20 nM siRNA (AllStars negative control, 30-
Alexa Fluor 488), vesicles (Lysotracker Red DND-99), and nuclei (Hoechst 34580) at 1 hr. (h) 1 mg/kg siRNA (AllStars negative control, 30-Alexa
Fluor 647), 640/700 nm ex/em at 24 hr. Images in (h) were obtained in a transillumination configuration which limits observable signal, here, to
the hind flanks. Error represents (b,c) SD of three technical, (f) SD of three biological, and (h) SD of four biological replicates
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75610% as measured using fluorescently labeled siRNA (AllStars Nega-
tive Control siRNA, Alexa Fluor 647; Qiagen, Hilden, Germany).
Photon correlation spectroscopy and laser Doppler electrophoresis
measurements were carried out in molecular biology grade deionized
water using a Malvern Zetasizer Nano ZS90 particle analyser
(k5633 nm, material/dispersant RI 1.590/1.330). Critical aggregation
concentration was determined as described previously32 using a four-
parameter logistic fit (kex5335 nm, kem,I15373 nm, kem,I35384 nm;
n53 replicates).
2.3 | In vitro studies
OVCAR8 cells were a gift from S. Bhatia (MIT). OVCAR3, Caov3, and
TOV-112D cells were obtained from ATCC. Cells were subcultured in
DMEM supplanted with 10% fetal bovine serum and penicillin/strepto-
mycin, or the supplier’s recommended basal medium, in a 5% CO2
humidified atmosphere. Lines were screened for mycoplasma (Swanson
Biotechnology Center, Cambridge, MA) and authenticated by short tan-
dem repeat analysis (Promega) both after viral transduction and prior to
tumor induction.
In vitro knockdown was assessed in COV362 cells following for-
ward transfection in OPTI-MEM media for 72 hr (10 nM siRNA) using
nanoplexes assembled as described above or Lipofectamine RNAiMAX
(Life Technologies) as formulated per the manufacturer’s recommended
conditions. shRNAs were designed using the Cold Spring Harbor web
portal33 and 97mer oligonucleotides were used as templates for PCR
using miR-30 shRNA amplification primers. The PCR product was
cloned into the miR30-based retroviral vector pMLP, a kind gift from
M. Hemann (MIT). The oligonucleotide for targeting MK2 (human,
NM_032960.2) was 50-TGCTGTTGACAGTGAGCGAAGCGAAATTGT
CTTTACTAAATAGTGAAGCCACAGATGTATTTAGTAAAGACAATTTC
GCTCTGCCTACTGCCTCGGA-30.
Colony formation assays were performed following treatment with
vehicle, cisplatin, or paclitaxel for 4 hr. TOV112D cells were then
washed, trypsinized, and re-plated at a concentration of 1,000 cells/
well for mock-treated groups and 10,000 cells/well for chemotherapy-
treated groups in a 6-well dish. After 10 days, cells were fixed and
stained with modified Wright-stain (Sigma-Aldrich). Colonies were
enumerated and surviving fractions were determined by normalization
with vehicle treated cells.
Tissue microarrays were obtained from Pantomics (OVC2281) and
processed/stained by the Swanson Biotechnology Center (Cambridge,
MA). Phospho-p38 antibodies were diluted as recommended by the
manufacturer.
2.4 | Retrovirus transduction
For VSVG-pseudotyped virus production, 293T cells were transfected
using the calcium phosphate method (Clontech) using pMLP along with
packaging and structural vectors VSVG and GAG/POL. Supernatants
containing virus were then used to transduce target cells in the pres-
ence of 8 lg/ml polybrene for three rounds of infection. Successfully
transduced cells were selected either with puromycin (3 lg/ml) for
pMLP infected cells, or were sorted for GFP expression by flow cytom-
etry for GFP-Luciferase used to infect OVCAR8 cells for bio-
luminescent imaging and was a gift from B. Huang (MIT).
2.5 | qRT-PCR
For qRT-PCR analysis, RNA was extracted from mouse tumor or cells
using TRIzol reagent (Ambion) according to the manufacturer’s instruc-
tions and 1 lg of total RNA was used for reverse transcription using
the Superscript III First-Strand Synthesis kit (Invitrogen) as per the man-
ufacturer’s instructions. For qPCR, data cDNA was amplified using
SYBR green PCR mastermix (Applied Biosystems) according to the
manufacturer’s cycling conditions for 40 cycles on a Bio-Rad C1000
Thermal Cycler. Data were analyzed using the delta-delta Ct method as
described previously and plotted as fold change versus control.34,35 Pri-
mers were ordered from Invitrogen and/or IDT: Actin hsa Fwd
gaaaatctggcaccacacc, Actin hsa Rev catactcctgcttgctgatc,
MK2 hsa Fwd gaagtgcctgctgattgtca, and MK2 hsa Rev tcaaa-
gagttgtggctggtg, GAPDH Fwd GAAGGTGAAGGTCGGAGTCAAC,
and GAPDH Rev CAGAGTTAAAAGCAGCCCTGGT.
2.6 | Western blot
Cells were lysed in RIPA lysis buffer containing protease and phospha-
tase inhibitor (Roche). Protein concentration was measured using BCA
(Pierce) and cell extracts containing the same amount of protein were
mixed with 63 reducing sample buffer, boiled at 958C for 5 min, and
subject to electrophoresis using standard SDS-PAGE methods. For
LICOR-based blotting, proteins were transferred to nitrocellulose mem-
branes (Biorad) and blocked with Odyssey blocking buffer for 1 hr. Pri-
mary antibodies were incubated overnight at 48C followed by
secondary antibodies conjugated with LICOR fluorophores, then
scanned with a LICOR/Odyssey infrared imaging system (LICOR Bio-
sciences). Band densitometries were quantified using ImageStudio. For
ECL-based blotting, proteins were transferred to methanol-activated
PVDF membrane (Biorad) and blocked with 5% nonfat dried milk for
1h. Primary antibodies were incubated overnight at 48C followed by
secondary antibodies conjugated with HRP for developing with ECL
(Perkin Elmer).
2.7 | Electron microscopy
0.125 nmol streptavidin-gold (1.4 nm; Nanoprobes) and 0.5 nmol
biotin-modified siRNA (Ambion Silencer Negative Control No. 1) were
reconstituted with peptide amphiphiles as described above and purified
by dialysis (50 kDa) against ultrapure water at 48C. TEM was carried
out using a JEOL 2100 FEG instrument at an accelerating voltage of
200 kV. Samples were prepared by dropcasting particle suspensions
onto a TEM grid with a QUANTIFOIL Holey Carbon Film (Electron
Microscopy Sciences). Cryogenic transmission electron microscopy
(TEM) was performed using a JEOL 2100 FEG instrument equipped
with a Gatan 626 Single Tilt Liquid Nitrogen Cryo Transfer Holder. Vit-
rified samples were prepared on QUANTIFOIL Holey Carbon Films
using a Gatan Cryo-Plunge3 system.
DREADEN ET AL. | 29
2.8 | Live-cell confocal fluorescence microscopy
Imaging was performed using a Nikon 1AR Ultra-Fast Spectral Scanning
Confocal Microscope equipped with an environmental chamber provid-
ing temperature control. Caov3 cells were passaged onto 35 mm glass-
bottom culture dishes (MatTek, no. 0). Adherent cells were washed with
DPBS and concurrently incubated with nanoplexes (50 nM, AllStars
Negative Control siRNA, Alexa Fluor 488; Qiagen), LysoTracker Deep
Red (50 nM, Thermo Fischer), and Hoechst 34580 (10 lg/ml, Thermo
Fischer) in Opti-MEM media at 378C for 1 hr. Cell monolayers were
then washed in DPBS and imaged in HEPES buffer (10 mM, pH 7.4).
2.9 | In vivo studies
Female NCr nu/nu and BALB/c mice (6 wks) were obtained from
Taconic. Orthotopic OVCAR8 tumors were induced in NCr nu/nu mice
following i.p. injection of 300 lL of DPBS cell suspensions containing
5 3 105 viable cells/mouse as measured by trypan blue exclusion. Sub-
cutaneous OVCAR3 tumors were induced in NCr nu/nu mice following
s.c. injection of 200 lL of DPBS:Matrigel (50% v/v) cell suspensions
containing 5 3 106 viable cells/flank as measured by trypan blue
exclusion. Tumors were treated after 4 weeks. siRNA accumulation
was approximated using a Xenogen IVIS Imaging System (Caliper).
Subcutaneous tumor-bearing mice (n53) were intraperitoneally
injected with nanoparticles (1 mg/kg, AllStars Negative Control
siRNA, Alexa Fluor 647; Qiagen) dispersed in PBS. After 24 hr, mice
were anesthetized with isoflurane and imaged (640/700 nm ex/em).
Recovered fluorescence from the rear flank and whole animal was
quantified using the region-of-interest analysis package in Living
Image (Perkin Elmer). siRNA accumulation in orthotopic tumors was
qualitatively imaged using a Typhoon Variable Mode Imager (ex 488,
em 555/20 nm; ex 633, em 670/30 nm). Bioluminescence imaging
was performed on a Xenogen IVIS Imaging System at 10 min follow-
ing i.p. injection of 300 lL of 15 mg/mL D-luciferin potassium salt
(Perkin Elmer) diluted in DPBS.
Tumor samples for flow cytometry were excised, minced using a scal-
pel, and dissociated in 2 mL of collagenase I (Gibco, 600 lg/mL) in HBSS
containing 3 mM CaCl2 for 18 hr at 378C with shaking. Suspensions were
filtered (40 lm), centrifuged, and washed twice in HBSS, then fixed in 4%
formaldehyde/PBS for 30 min at 378C, prior to centrifugation and dilution
in 1% BSA/PBS. Samples were analyzed on a BD LSR II flow cytometer.
Histological tissue samples were excised, immediately fixed in for-
malin for 72 hr, and stored in 70% v/v ethanol prior to paraffin-
embedding, processing, and immunostaining by the Swanson Biotech-
nology Center (MIT). Primary antibodies were diluted per the manufac-
turer’s recommended conditions. Slides were scanned using a Leica
Biosystems Aperio Digital Pathology Slide Scanner.
Serum samples were obtained at the study endpoints using BD
microtainer SST tubes and frozen at 2808C prior to analysis by MIT’s
Comparative Pathology Laboratory. Ascites samples were obtained at
the study endpoints and cells/debris were removed by centrifugation
(800 g, 10 min). Samples were frozen at 2808C prior to MCP-1 analysis
by Eve Technologies (Calgary, AB, Canada).
Mice received cisplatin (Sigma-Aldrich) and paclitaxel (LC Labs) as
indicated (i.p., 300 lL/mouse). Paclitaxel was solubilized in Cremaphor
EL:ethanol (50% v/v). Cisplatin was solubilized in DPBS. Total Crema-
phor EL : ethanol content was <1% v/v of the injection volume.
Study endpoints included poor body condition (BC<2), abdominal
distension that impeded mobility (as determined by DCM veterinary
staff), as well as bioluminescence flux that exceeded burden corre-
sponding to 1,000 mm3 of excisable tumor volume. These experiments
were approved by the Massachusetts Institute of Technology Commit-
tee on Animal Care.
3 | RESULTS AND DISCUSSION
3.1 | Rational design of an RNA-peptide nanoplex
To achieve in vivo RNAi, we engineered a peptide-based nanoplex com-
posed of end-functional NCA polymers. Ring-opening polymerization of
benzyl L-aspartate NCA and subsequent deprotection or methylation,
yielded three distinct amphiphilic peptides (Figure 1a, Supporting Infor-
mation Figure S1a). Here, hydrophobic tails of all three amphiphiles
were composed of poly(benzyl L-aspartate), while hydrophilic head
groups comprised either a monovalent quaternary ammonium salt, a
short linear poly(ethylene oxide) chain, or a zwitterionic alanine moiety.
The cationic ammonium group was included to facilitate electrostatic
complexation with the phosphate backbone of siRNA and a 5 kDa poly
(ethylene oxide) block was designed to facilitate steric shielding from
endo- and exonucleases in the blood. A zwitterionic head group, a moi-
ety commonly employed in so-called “helper” or “fusogenic” lipids,36
was included here to facilitate entry of siRNA into the cytosol following
cellular uptake, where bound nucleic acids can interact with proteins-
associated with the RNA-induced silencing complex (RISC).
Peptide nanoplexes were formed by a modified ethanol dilution37
method (see Methods for details). Peptide-siRNA nanoplexes obtained
at an N-to-P ratio of 1 were 90611 nm in hydrodynamic diameter and
nominally neutral in surface charge (2464 mV) with relatively narrow
polydispersity, as measured by dynamic light scattering (Figure 1b,c).
Oligonucleotide loading and encapsulation efficiency were 0.48 wt%
and 75610%, respectively, as measured by RiboGreen assay. Cryo-
genic transmission electron microscopy (cryo-TEM) of hydrated nano-
plexes supported these size measurements and further indicated a
spherical morphology (Figure 1d, Supporting Information Figure S1b).
Electron microscopy of dehydrated nanoparticles formed using siRNA
labeled with 1.4 nm gold nanoparticles further suggested that oligonu-
cleotides were spatially distributed evenly throughout a complex core
(Figure 1e, Supporting Information Figure S1c). This morphology is pre-
sented in contrast to a more traditional micellar or lamellar core-shell
structure in which siRNA complexation is expected to be limited to the
outer surface or leaflet bilayer. This less organized but uniform morphol-
ogy suggests strong interactions between siRNA and the charged and
hydrophobic blocks to yield a blended core nanoparticle which we
hypothesize enables more facile intracellular release of siRNA. The criti-
cal aggregation concentration of these peptide-siRNA suprastructures
was 1867 mM as measured by pyrene fluorescence assay,
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approximately 2.3-fold greater than the estimated minimum initial blood
concentration following systemic (e.g., intravenous) administration at
1 mg/kg siRNA in mice (Figure 1f). The resulting nanoparticle system
was designed for intraperitoneal administration in which nanoparticles
would be more directly exposed to tumor sites; therefore, in these initial
studies, a specific tumor cell targeting ligand was not incorporated.
In vitro, nanoplex-transfected OC cells exhibited diffuse, cytoplas-
mic fluorescence, as well as puncta colocalized with acidic organelles
(Lysotracker), when fluorescently labeled siRNA was complexed and
delivered to cells in culture (Figure 1g, Supporting Information Figure
S1d). In vivo, peptide nanoplexes targeted subcutaneous ovarian tumor
xenografts with high efficiency following systemic (intraperitoneal)
administration of control siRNA labeled with a near-infrared fluorophore
(1 mg/kg siRNA). Fluorescence tomographic imaging indicated spatial
penetration of siRNA throughout ovarian tumor xenografts (Figure 1h,
Supporting Information Figure S1e) and corresponding epifluorescence
imaging analysis found that 4.860.8% of the injected dose (i.e., recov-
ered fluorescence) co-localized with the tumors (t524 hr, n54).
3.2 | Loss of MK2 chemosensitizes ovarian tumor cells
Having established a suitable platform for in vivo RNAi, we next sought
a therapeutic target that was not currently druggable using small mole-
cules, and whose functional silencing could improve treatment out-
comes in patients currently receiving frontline chemotherapy for OC.
We previously showed that pairwise loss of p53 and MK2 was syntheti-
cally lethal in chemotherapy-treated, non-small cell lung tumors;28
however, at present it was unclear to what extent these findings extend
to other tumor types. We hypothesized that an MK2-dependent DNA
damage response would likewise be required for survival in chemother-
apy treated ovarian tumors that are genotypically characterized by loss-
of-function p53 mutations. Indeed, we found that activation of MK2’s
upstream signal effector, p38, was significantly enriched in serous ovar-
ian tumors relative to matched normal tissues (Supporting Information
Figure S2) and that clonogenicity of p53-mutant ovarian tumor cells
(TOV112D) was dramatically diminished following shRNA-mediated
MK2 depletion and platinum or taxane treatment in vitro (Figure 2a–c,
Supporting Information Figure S3). Together, these findings provide
strong support that loss of MK2 can chemosensitize p53-mutant ovar-
ian tumors to frontline therapeutic interventions for the disease (i.e.,
platinum/taxane doublet therapy). In vitro, we also observed nominally
improved MK2 silencing efficiency from RNA-peptide nanoplexes com-
pared with commercial cationic lipid-based transfection reagents (i.e.,
Lipofectamine RNAiMAX) at equimolar siRNA concentrations (COV362,
10 nM, 72 hr; Figure 2d), demonstrating efficient cytosolic delivery rela-
tive to known, non-viral delivery vectors.
3.3 | Peptide nanoplexes deliver siRNA to mouse
models of OC
In order to assess the therapeutic benefits of nanoplex-mediated RNAi
of MK2, we next established a mouse model of OC that faithfully reca-
pitulates the genetic and histopathologic features of high-grade serous
disease. Shultz and coworkers38 recently identified a subset of OC cells
FIGURE 2 Loss of MK2 chemosensitizes ovarian tumor cells to platinum/taxane therapy in vitro. MK2-dependent colony formation follow-
ing pulsed exposure to (a) cisplatin or (b) paclitaxel relative to TOV-112D cells transduced with control shRNA. (c) Real-Time PCR (qPCR)
and Western blot of MK2-depleted cells from (a,b) demonstrating mRNA and protein downregulation. (d) RNA-peptide nanoplex depletion
MK2 mRNA with efficiency equal to or better than commercial transfection reagents (i.e., Lipofectamine RNAiMAX). (d) COV362, 10 nM, 72
hr. Error represents SEM of three replicates
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that — in contrast to lines often employed — more closely resembles
the copy-number changes, mutations, and mRNA expression profiles
presented by high-grade serous ovarian tumors. We39 and others40,41
later identified cell lines among these whose phenotypic and histopath-
ological features, in vivo, further aligned with that of the human dis-
ease. In these studies, we selected the OVCAR8 cell line due to its
relatively aggressive growth rate, strongly mesenchymal phenotype,
ability to form intraperitoneal tumors with high-grade histopathological
features, and murine disease accompaniment by ascitic fluid accumula-
tion. To facilitate longitudinal monitoring of tumor-bearing mice, paren-
tal OVCAR8 cells were transduced with a retroviral vector expressing
GFP and firefly luciferase. OVCAR8-GFP-fLuc cells formed excisable
tumors approximately 28 days following intraperitoneal implantation
into athymic NCr nude mice (5 3 105 cells, Figure 3a) with ascites
accumulation at 28–91 days post implantation. In all cases, tumors
were spread throughout the abdominal cavity and seeded sites largely
coincident with the human disease including the bowel/colon, perito-
neum, liver, diaphragm, and mesentery (Figure 3b,c). OVCAR8 tumors
displayed immunohistochemical markers of rapid proliferation (Ki67)
and lineage-specific markers of the ovarian surface epithelium (WT1,
Supporting Information Figure S4). Although tumor lesions in untreated
mice were typically intra-abdominal, those without significant ascites
accumulation often exhibited extraperitoneal (i.e., stage IV) disease at
the study endpoints (median survival 59 days; Supporting Information
Figure S5).
Following development of this orthotopic mouse model of high-
grade serous OC, we next examined the efficiency of systemic siRNA
delivery to locally disseminated ovarian tumors. Using near-infrared flu-
orophore-labeled siRNA, we observed spatial co-registry between GFP
tumor fluorescence and siRNA fluorescence following systemic intra-
peritoneal administration of peptide nanoplexes (1 mg/kg siRNA;
Figure 3d). Tumor dissociation and flow cytometric analysis revealed
that 7765% of the GFP1 tumor cell population also stained positive
for siRNA (Figure 3e). This high fraction of tumor cells that receive
siRNA is encouraging as heterogeneous delivery could diminish chemo-
sensitization effects in vivo. We hypothesize that the high efficiency
with which peptide nanoplexes deliver siRNA here is mediated, in part,
by direct intra-abdominal tumor exposure following intraperitoneal
administration. Interestingly, and in contrast to other tumor types, OC
chemotherapy is frequently administered via intraperitoneal infusion as
FIGURE 3 Nanoplex-mediated siRNA delivery in an orthotopic mouse model of high-grade serous ovarian cancer. Representative
growth of orthotopically implanted OVCAR8 tumors as monitored by (a) bioluminescence imaging and (b) diffuse light imaging tomogra-
phy (DLIT). (c) Anatomic sites of OVCAR8 tumor dissemination observed relative to the human disease. (d) Spatial co-registry between
siRNA (red) and tumor (green) fluorescence at 24 hr following nanoplex-mediated siRNA delivery as measured by fluorescence imaging.
(e) In vivo siRNA delivery efficiency as measured by flow cytometry of parental cells (top), GFP-transduced cells (middle), and excised
tumor tissues (bottom). Double positive cells in (e) represent 7765% of the GFP1 single-cell population following nanoplex-mediated
siRNA delivery (1 mg/kg, i.p, 24 hr). OVCAR8 cells were retrovirally transduced to express enhanced green fluorescent protein (eGFP)
and firefly luciferase (fLuc). Note that kinetics in panel (a) reflect average growth from independent biological replicates and that tumor
localization over time may not necessarily coincide; 5 3 105 cells/mouse. Time scale in (a) denotes growth kinetics over tumor induc-
tion and treatment (sham) phases. Image in (b) obtained at Day 42 post-implantation. (d) AllStars negative control siRNA, 30-Alexa Fluor
647; 488/555 nm ex/em (eGFP), and 633/670 nm ex/em (siRNA). (e) AllStars negative control siRNA, 30-Alexa Fluor 488
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this method affords higher selectivity and improved tumor access com-
pared with intravenous chemotherapy.42,43 Thus, delivery of ovarian
tumor-directed nanoplexes by this method may be incorporated more
readily into existing treatment protocols than in other tumor types.
3.4 | Neoadjuvant siMK2 therapy improves OC
treatment outcomes
After demonstrating efficient in vivo delivery of siRNA to orthotopic,
high-grade serous ovarian tumor models, we next investigated treat-
ment outcomes in OVCAR8 tumor-bearing mice. In prior work,44 we
observed robust silencing of MK2 over Days 2–5 following in vitro
siRNA delivery. Thus, weekly treatment cycles consisted of siRNA
(1 mg/kg, BIW) on Monday/Friday and cisplatin/paclitaxel (2.3/6.0 mg/
kg, QW) on Wednesday (Figure 4a). Chemotherapeutic drugs, cumula-
tive stoichiometric ratios, and excipients employed here were consist-
ent with current National Comprehensive Cancer Network (NCCN)
treatment guidelines45 for intraperitoneal OC chemotherapy (stages II–
IV). A relatively modest dose of cisplatin was used in this case as
OVCAR8 is a platinum-sensitive41 cell line.
Following induction, OVCAR8 tumor-bearing mice received plati-
num/taxane chemotherapy with or without concurrent nanoplex-
FIGURE 4 Nanoplex-mediated RNA interference of MK2 sensitizes high-grade serous ovarian tumors to platinum/taxane chemotherapy in
vivo and improves overall survival. (a) Treatment schedule and (b) Kaplan–Meier survival curves for OVCAR8 tumor-bearing mice receiving
nanoplex therapy with or without concurrent cisplatin/paclitaxel therapy. Corresponding (c) median survival and (d) percent body weight
change associated with varying treatment arms. (e) Tumor burden at treatment cessation (Day 28) as measured by bioluminescence imaging.
Immunohistochemical staining of (f) parenchymal MK2, (g) Ki-67, and (h) cleaved caspase-3 at treatment cessation. (i–k) Serum biochemistry
from mice receiving combined nanoplex/chemotherapy (purple) or chemotherapy alone (red) as measured at study endpoints. (l) Immunohis-
tochemical staining of lung tissues obtained from mice at study endpoints displaying pulmonary metastases positive for a lineage-specific
marker of the ovarian surface epithelium (PAX8). (m) Ascitic MCP-1 levels obtained from mice at study endpoints. (i–k) gray boxes denote
normal reference ranges. (l) T denotes tumor regions. Error represents (d) mean6 SEM of 5–10 biological replicates and (m) mean6 SEM of
3–7 biological replicates. p< .05(*), p< .01(**), p< .001(***)
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siRNA therapy for four weekly cycles, then were monitored for 180
days (Figure 4b). Although nanoplex-siRNA monotherapy significantly
improved median survival relative to untreated controls, outcomes
were nominally less-favorable than chemotherapy alone (94 vs. 129
days). In contrast, combined nanoplex-siRNA and chemotherapy greatly
improved treatment outcomes compared with chemotherapy alone,
extending median survival by 37% (48 days, 177 days total) in the
absence of acute toxicity as measured by fractional body weight loss
(Figure 4c,d). Tumor burden as measured from bioluminescence images
obtained at treatment cessation (Figure 4e) agreed well with observed
trends in overall survival.
Immunohistochemical analysis of tumors excised at treatment ces-
sation also agreed well with the corresponding treatments outcomes
and 1.37-fold increased survival times (Figure 4f–h). Mice receiving
chemotherapy alone exhibited decreased tumor proliferation (Ki-67) and
increased apoptotic cell killing (cleaved caspase-3). Parenchymal MK2
levels in tumors treated with nanoplex-siRNA monotherapy were nota-
bly diminished, while tumor proliferation and apoptosis were generally
comparable with chemotherapy-treated tumors. Mice receiving concur-
rent siMK2 therapy and chemotherapy exhibited the most dramatic
decreases in tumor proliferation and increases in cell killing.
Having shown that nanoplex-mediated RNAi of MK2 chemosensi-
tized ovarian tumors to frontline chemotherapy in vivo, we next exam-
ined differential pharmacodynamics that may have predicated improved
treatment outcomes in mice receiving combined siRNA and chemother-
apy. In prior work (unpublished), we found that repeated intraperitoneal
dosing of nanoplex-siMK2 (1 mg/kg siRNA, BIW) did not significantly
affect serum biochemical markers of liver and kidney damage.44 At the
study endpoints, we observed no significant differences in serum bio-
chemistry from mice receiving chemotherapy alone or that with those
receiving concurrent RNAi therapy (Figure 4i–k). Renal and hepatic
function was impaired in both groups; however, we could not attribute
differential survival to varying morbidity as measured from sera. We
also examined lung tissues obtained from mice that reached study end-
points. Immunohistochemical staining of these tissues using an ovarian
lineage-specific marker (PAX8) found no observable pulmonary metasta-
ses in mice receiving combined siMK2 and chemotherapy, while multi-
ple tumor lesions were observed in all other groups (Figure 4l).
Moreover, we found that ascitic fluids from mice obtained at study end-
points were significantly enriched in monocyte chemoattractant protein
1 (MCP-1, CCL2) following treatment with combined RNAi/chemother-
apy versus chemotherapy alone (p5 .0384; Figure 4m). Interestingly,
ascitic MCP-1 elevations were absent in mice treated with peptide
nanoplexes, alone. Additional, independent studies are currently under-
way to better understand the molecular mechanisms by which loss of
MK2 modulates tumor invasiveness and overall survival in OVCAR8
tumor-bearing mice that receive platinum/taxane chemotherapy.
4 | CONCLUSIONS
Peptide nanoplexes are a promising, modular drug delivery platform
that can enable enhanced tumor accumulation of a wide range of
therapeutics including small molecules, siRNA, plasmid DNA, and
mRNA.5,15,46,47 Here, we show that a novel polymer blend architecture
consisting of three NCA peptide homologs can self-assemble to form
stable siRNA nanoplexes that silence a key DNA-damage response
pathway in p53-deficient advanced ovarian tumors. Nanoplex-
mediated silencing of MK2 profoundly sensitized high-grade serous
ovarian tumors to concurrent platinum/taxane chemotherapy in vivo,
improved overall survival by 37%, and decreased metastatic spread to
the lungs without observable toxic side effects.
Given their peptide backbone and FDA GRAS (generally regarded
as safe) designation of their amino acid metabolites, these structures
could serve as uniquely biocompatible alternatives to conventional,
non-natural siRNA delivery vectors. Kataoka and coworkers, for exam-
ple, have shown that chemotherapy-appended NCA polypeptides are
well-tolerated in patients both in the United States48 and in Japan,49–51
and protein-mimetic NCA polypeptides such as glatiramer acetate have
been approved for clinical use in the United States since 1997. In con-
trast to peptides synthesized by solid-phase techniques or those pro-
duced through recombinant expression, the RNAi delivery technologies
described here could be manufactured both in large-scale and with
diverse (i.e., non-natural) chemical functionality, potentially enabling
more facile commercial development.
Therapeutic inhibition of MK2 also holds promise for a range of
other disease indications beyond that demonstrated here in ovarian
tumors. Duvall and coworkers, for example, have shown that polymer-
mediated delivery of peptide inhibitors of MK2 can block intimal hyper-
plasia and failure of autologous vein graft transplants in rabbits, a pro-
cedure commonly used for coronary and peripheral artery bypass in
patients.52 There, inhibition of the p38/MK2 pathway-mediated stress
response induced following graft harvest/transplantation greatly
decreased profibrotic response and corresponding graft failure. Inhibi-
tion of MK2 using small molecule tool compounds has also been shown
to synergize with blockade of other cell cycle checkpoint kinases in
Ras-driven solid tumors, augmenting tumor cell killing in a p53-
dependent manner.53 The discovery of safe and specific small molecule
inhibitors of MK2 for rheumatoid arthritis54 therapy is also an active
area of industrial research. RNAi-mediated silencing of MK2 may obvi-
ate the need for such development as small molecules targeting MK2
have historically exhibited off-target toxic effects and limited selectiv-
ity. Given the promising results shown here, we anticipate that peptide
nanoplex-mediated RNAi may serve as a safe, specific, and effective
neoadjuvant therapy that can sensitize advanced ovarian — and other
solid — tumors to frontline cytotoxic chemotherapy.
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